Tenofovir
- Generic Name
- Tenofovir
- Brand Names
- Vemlidy, Tenofovir disoproxil Zentiva
- Drug Type
- Small Molecule
- Chemical Formula
- C9H14N5O4P
- CAS Number
- 147127-20-6
- Unique Ingredient Identifier
- W4HFE001U5
- Background
Tenofovir is an acyclic nucleotide diester analog of adenosine monophosphate. In the most strict sense and due to the fact that it presents a phosphate group bound to the nitrogenous base, it is determined as an actual nucleotide analog. The antiviral activities of tenofovir were first reported in 1993 and this agent was commercially available since 2008 in ...
- Indication
Tenofovir has been shown to be effective against HIV, herpes simplex virus-2, and hepatitis B virus.
To know more about the specific product indications, please visit the information in the orally available forms of tenofovir, tenofovir alafenamide and tenofovir disoproxil.
- Associated Conditions
- -
- Associated Therapies
- -
New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects
- Conditions
- First Posted Date
- 2002-09-04
- Last Posted Date
- 2020-03-24
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 166
- Registration Number
- NCT00044577
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Conditions
- Interventions
- Drug: darunavir/ritonavir dosage #1Drug: TAF w/cobicistatDrug: TAF w/cobicistat or ritonavirDrug: tenofovir alafenamide fumarate (TAF)Drug: elvitegravir/cobicistatDrug: darunavir/cobicistatDrug: atazanavir/cobicistatDrug: lopinavir/ritonavir dosage #1Drug: atazanavir/ritonavir/tenofovir dosage #1Drug: lopinavir/ritonavir dosage #2Drug: indinavir/ritonavir dosage #1Drug: fosamprenavir/ritonavirDrug: atazanavir/ritonavir dosage #1Drug: didanosine delayed release (Videx® EC)Drug: emtricitabineDrug: nelfinavir dosage #1Drug: tipranavir/ritonavirDrug: etravirineDrug: darunavir/ritonavir dosage #4Drug: indinavir/ritonavir dosage #2Drug: rilpivirineDrug: ethambutolDrug: efavirenzDrug: raltegravirDrug: dolutegravirDrug: kanamycinDrug: nevirapineDrug: amprenavirDrug: abacavirDrug: tenofovirDrug: maravirocDrug: darunavir/ritonavir dosage #2Drug: lopinavir/ritonavir dosage #3Drug: lopinavir/ritonavir dosage #4Drug: tenofovir/atazanavir/ritonavir dosage #2Drug: atazanavir/ritonavir dosage #2Drug: nelfinavir dosage #2Drug: rifampicinDrug: amikacinDrug: darunavir/ritonavir dosage #3Drug: etonogestrel implantDrug: capreomycinDrug: ethinyl estradiolDrug: isoniazidDrug: moxifloxacinDrug: levoflaxacinDrug: pyrazinamideDrug: ofloxacinDrug: ethionamide/prothionamideDrug: terizidone/cycloserineDrug: para-aminosalicylic acid (PAS)Drug: high dose INHDrug: bedaquilineDrug: clofazamineDrug: delamanidDrug: linezolidDrug: pretomanid
- First Posted Date
- 2002-08-01
- Last Posted Date
- 2022-07-22
- Target Recruit Count
- 1578
- Registration Number
- NCT00042289
- Locations
- 🇺🇸
Usc La Nichd Crs, Los Angeles, California, United States
🇿🇦Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa
🇺🇸Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States
Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure
- Conditions
- First Posted Date
- 2002-06-03
- Last Posted Date
- 2015-04-08
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 100
- Registration Number
- NCT00038506
- Locations
- 🇺🇸
GSK Investigational Site, Green Bay, Wisconsin, United States
Safety and Acceptability of the Anti-Microbe Vaginal Gel, PMPA Gel
- Conditions
- First Posted Date
- 2001-12-14
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 120
- Registration Number
- NCT00028132
- Locations
- 🇺🇸
3535 Market Street CRS, Philadelphia, Pennsylvania, United States
🇺🇸Bronx- Lebanon Hospital Center Clinical Research Site (BLHC CRS), Bronx, New York, United States
🇺🇸The Miriam Hosp., Div. of Infectious Disease, Providence, Rhode Island, United States
A Study of PMPA in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT00002180
- Locations
- 🇺🇸
Johns Hopkins Univ, Baltimore, Maryland, United States
🇺🇸San Francisco Gen Hosp / AIDS Program, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.